Press Releases

GlobeNewswire, Inc.

Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines...

GlobeNewswire, Inc.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Wise Group plc (“Wise Group” or the “Company”) (NASDAQ: WSE) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at...

GlobeNewswire, Inc.

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds investors who purchased Microvast Holdings, Inc. (“Microvast” or the “Company”) (NASDAQ: MVST) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at...

GlobeNewswire, Inc.

HOLMDEL, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, announced its second quarter (Q2’26) and first half...

GlobeNewswire, Inc.

SAN JOSE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- zSpace, Inc. (OTC: ZSPC) (“zSpace” or the “Company”), a leading provider of augmented and virtual reality (AR/VR) solutions for education and workforce development, is announcing its financial...

GlobeNewswire, Inc.

EL DORADO HILLS, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Blaize Holdings, Inc. (NASDAQ: BZAI, NASDAQ: BZAIW) (“Blaize,” the “Company,” “we,” “us,” and “our”) , a leader in programmable, energy-efficient edge AI computing, today reported...

GlobeNewswire, Inc.

Revenues were up 20% year over year, reaching $1.1 million in the second quarter of 2026; gross margin was 51%, compared to 32% in the second quarter of 2025 New wins across Intelligent Transportation Systems (ITS), U.S. carriers, and...

GlobeNewswire, Inc.

Commercialization execution advances in Rice and Sustainable Ingredients United States and European Union now aligned on generally treating crops with no added foreign DNA as conventionally bred Quarterly net cash usage declined 19% sequentially...

GlobeNewswire, Inc.

FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal...

GlobeNewswire, Inc.

– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs...

GlobeNewswire, Inc.

Key Takeaways: Parsons was awarded a $70 million task order under the U.S. Air Force's Air Base Air Defense (ABAD) contract to provide integration, testing, deployment, maintenance, and operational transition support for U.S. Air Forces in the...

GlobeNewswire, Inc.

Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial...

GlobeNewswire, Inc.

PONTE VEDRA, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today...

GlobeNewswire, Inc.

SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided...

GlobeNewswire, Inc.

Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.

GlobeNewswire, Inc.

IRVING, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company orchestrating mission-critical systems that enable hyper-automation and...

GlobeNewswire, Inc.

Deramiocel Biologics License Application (BLA) under active FDA review HOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achieved at p=0.029 Cash, cash equivalents and marketable securities of approximately...

GlobeNewswire, Inc.

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026 Phase 3...

GlobeNewswire, Inc.

Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data presentations at ESMO planned for MGC026...

GlobeNewswire, Inc.

-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with 2L LBCL...